

with proliferative diabetic retinopathy and chronic kidney disease: a possible side effect? *Curr Drug Saf.* 2014;9:156–8.

10. Cheungpasitporn W, Chebib FT, Cornell LD, Brodin ML, Nasr SH, Schinstock CA, et al. Intravitreal antivascul endothelial growth factor therapy may induce proteinuria and antibody mediated injury in renal allografts. *Transplantation.* 2015;99:2382–6.

Enrique Morales*, Candela Moliz, Eduardo Gutierrez

Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, Spain

*Corresponding author.

E-mail address: emorales@senefro.org (E. Morales).

2013-2514/© 2016 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<http://dx.doi.org/10.1016/j.nefro.2017.10.007>

Immediate re-transplantation: An audacious approach to early vascular renal transplant failure[☆]

Trasplante exprés: un tratamiento audaz en el fallo técnico precoz del injerto

Dear Editor,

Renal transplantation is the treatment of choice in patients with advanced chronic kidney disease (CKD) as it improves the quality of life and survival of patients.¹

Vascular complications of renal transplantation represent an important cause of morbidity and mortality, and frequently lead to early graft loss,² which is around 5% in the most recent series.³ A 4–10% of patients who start dialysis have a non-functioning kidney graft, and up to 32% of cases require transplantectomy for various reasons.⁴ The mortality of these patients is greater than those with functional graft or in renal replacement therapy without previous transplantation.⁵ Current indications for transplantectomy include early graft loss, intolerance syndrome, severe proteinuria, recurrent pyelonephritis, neoplasia, and chronic inflammation syndrome.⁶ Early vascular complications of transplantation may cause the loss of the graft and the need for transplantectomy.

The performance of express transplant seeks to obtain the benefit of performing an inevitable transplantectomy with the implantation of another graft in the same surgical act. This improves both quality of life and survival of the patient,⁵ in addition to ameliorating the psychological problem of early graft loss.

In patients with terminal liver disease, re-transplantation after early graft loss is common otherwise the prognosis is very poor.⁷ In renal transplantation, such a degree of urgency does

not exist due to the availability of other renal replacement techniques,¹ thus re-transplantation is not performed early.

The term express used here as the definition made by the Royal Spanish Language Academy “with maximum speed”.⁸

We have performed a total of 4 express transplants over a period of 2 years, describing their characteristics and evolution in *Table 1*.

The immediate loss of the graft is included among the indications of transplantectomy and, in this case, it must be performed rapidly, since this almost immediate intervention can prevent foreseeable complications such as graft intolerance, rupture of the graft, infections and formation of antibodies ensuing hyperimmunization of the patient.^{6,9}

Performance of express transplant has several advantages: it avoids the morbimortality of the transplantectomy as a necessary but isolated act, since in the same act another transplant is carried out, immunosuppression is maintained which prevents the formation of antibodies and the hyperimmunization of the patient and finally it avoids the negative psychological impact of graft loss and preserves the confidence of patient on the actual medical care.

Prior to the procedure, it is important to rule out other causes of early graft loss, such as hyperacute rejection,¹⁰ or problems with hypercoagulability⁹ since both situations would contraindicate express transplantation. In our cases, the immunological study carried out after graft loss, the histological absence of acute rejection and the lack of history of

DOI of original article:

<http://dx.doi.org/10.1016/j.nefro.2017.03.016>.

[☆] Please cite this article as: Franco A, Rodríguez Santarelli D, Sanz J, Muñoz C, García Tabar P, Pérez Contreras J. Trasplante exprés: un tratamiento audaz en el fallo técnico precoz del injerto. *Nefrología.* 2017;37:655–657.

Table 1 – Summary of case description of transplant “express”.

	Case 1	Case 2	Case 3	Case 4
Recipient gender	Male	Male	Male	Male
Age	65	64	36	33
Type of RRT pre Tx	PD	HD	Pre-D	Pre-D
Cause of CKD	NAE	TIN	FSG	ND
1st donor	Cadaveric	Cadaveric	Alive	Cadaveric
2nd donor	Cadaveric	Cadaveric	Cadaveric	Cadaveric
Cause of graft failure	Vein T.	Vein T.	Arterial T.	Arterial T.
Time between transplants (h)	336	62	15	44.5
Time Cold ischemia 2nd graft (h)	14	17	16	14
Immunosuppression	TG, MFM, FK and P	TG, MFM, FK and P	TG, MFM, FK and P	TG, MFM, FK and P
Acute rejection	No	No	No	No
P Cr at discharge	2.3 mg/dl	2.04 mg/dl	1.62 mg/dl	2.6 mg/dl
P Cr at the end of follow-up (19months)	1.15 mg/dl (19 months)	2.15 mg/dl (15 months)	1.43 mg/dl (13 months)	2.2 mg/dl (12 months)

P Cr: plasma creatinine; PD: peritoneal dialysis; CKD: chronic kidney disease; FSG: focal and segmental glomerulosclerosis; HD: hemodialysis; MFM: mycophenolate mofetil; NAE: nephroangiosclerosis; ND: diabetic nephropathy; TIN: tubulointerstitial nephritis; P: prednisone; Pre-D: predialysis; T: thrombosis; TG: thymoglobulin; RRT: renal replacement therapy; Tx: transplantation.

thrombotic events in the recipients, reasonably ruled out these causes.

This type of transplantation requires a potent immunosuppression together with strict immunological study of the donor and recipient to reduce compatibility requirements given the time constraint to perform the transplant within the immediate postoperative period. The immunological study should include the detection of specific donor antibodies that could have been generated with the first transplantation and its characterization, since the presence of an infarcted graft stimulates the production of these antibodies.¹⁰

All our recipients of express transplant received immunosuppression with thymoglobulin. Phelan et al.⁹ have reported a series of cases with similar characteristics as ours, there were 9 cases collected over a period of 20 years. These patients had early graft loss due to vascular complications and were reimplanted in the subsequent days. Our series include cases in which transplantation was completed in a much shorter period of time, which provides more homogeneity than the Phelan series. In Phelan series the transplantectomy was not performed in the same surgical procedure as the retransplantation, which undermines the effectiveness of the strategy. In addition, the aforementioned series differs from ours in that the immunosuppression used in the second transplant only included induction with antibodies in 2 out of the 9 cases. This resulted in an acute rejection of 30% in the total series and in almost half (42.8%) of the patients without induction; thus the cause of graft loss. This experience reaffirms the strategy of administration a powerful immunosuppression to our patients, with a 0% rate of acute rejection and graft loss due to this cause.

The strategy of express transplantation depends on the availability of renal grafts in sufficient quantity and frequency in order to perform the re-transplantation within the immediate postoperative period. These conditions are fulfilled in our environment.¹¹

Our experience has been positive and lead us to the individualized but systematic evaluation of all recipients with early

graft failure secondary to vascular complications as potential candidates to undergo express transplantation

REFERENCES

1. Wolfe RA, Sabih VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LYC, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. *N Engl J Med.* 1999;341:1725–30.
2. Bakir N, Sluiter WJ, Ploeg RJ, van Son WJ, Tegzess AM. Primary renal graft thrombosis. *Nephrol Dial Transplant.* 1996;11:140–7.
3. García de Jalón Martínez Á, Pascual Regueiro D, Trivez Boned MA, Sancho Serrano C, Mallén Mateo E, Gil Martínez P, et al. Trasplante renal. Técnica y complicaciones. *Actas Urol Esp.* 2003;27:662–77.
4. Pérez-Flores I, Sánchez-Fructuoso A, Marcén R, Fernández A, Fernández Lucas M, Teruel JL. Manejo del injerto renal fallido. Nefrectomía versus embolización. *Nefrología.* 2009;29 Supl 1:S54–61.
5. Kaplan B, Meier-Kriesche H-U. Death after graft loss: an important late study endpoint in kidney transplantation. *Am J Transplant.* 2002;2:970–4.
6. Antón-Pérez G, Gallego-Samper R, Marrero-Robayna S, Henríquez-Palop F, Rodríguez-Pérez JC. Transplantectomy following renal graft failure. *Nefrología.* 2012;32:573–8, <http://dx.doi.org/10.3265/Nefrología.pre2012.Jun.11100> [review; in English/Spanish].
7. Uemura T, Randall HB, Sanchez EQ, Ikegami T, Narasimhan G, McKenna GJ, et al. Liver retransplantation for primary nonfunction: analysis of a 20-year single-center experience. *Liver Transpl.* 2007;13:227–33.
8. Real Academia Española. Diccionario de la lengua española. 22nd ed; 2001. Available from: <http://www.rae.es/rae.html>
9. Phelan PJ, Magee C, O'Kelly P, O'Brien FJ, Little D, Conlon PJ. Immediate re-transplantation following early kidney transplant thrombosis. *Nephrology.* 2011;16:607–11.
10. Marcen R, Teruel JL. Patient outcomes after kidney allograft loss. *Transplant Rev (Orlando).* 2008;22:62–72.
11. Registro Español de Enfermos Renales. Registro Español de Enfermos Renales [online]. Available from: <http://www.registrorenal.es> [accessed 1.2.15].

Antonio Franco^{a,*}, David Rodríguez Santarelli^a, Jaime Sanz^a, Carlos Muñoz^b, Pedro García Tabar^c, Javier Pérez Contreras^a

^a Servicio de Nefrología, Hospital General de Alicante, Alicante, Spain

^b Servicio de Inmunología, Hospital General de Alicante, Alicante, Spain

^c Servicio de Urología, Hospital General de Alicante, Alicante, Spain

*Corresponding author.

E-mail address: franco_ant@gva.es (A. Franco).

2013-2514/© 2017 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<http://dx.doi.org/10.1016/j.nefro.2017.11.004>

Acute renal failure in a tertiary referral hospital, a relevant cause of chronic renal failure and mortality[☆]

Fracaso renal agudo en un hospital de tercer nivel, causa relevante de enfermedad renal crónica y mortalidad a medio plazo

Dear Editor,

The onset of acute renal failure (ARF) in a hospitalised patient is an important independent factor of morbidity/mortality and development of chronic kidney disease (CKD), and, therefore, preventive measures are essential for reducing their frequency.¹⁻³

Our aim was to analyse episodes of ARF in our department followed as referrals and their mid-term outcome.

This is a retrospective cohort study in which the referrals due to ARF requested to our department for a 10-month period (April 2013–January 2014), as well as their evolution over the following two years, were analysed.

We analysed the following variables: age, gender, comorbidity, kidney function, average duration of hospitalisation, need for haemodialysis, risk factors and mortality. To do this, we reviewed the electronic medical record (EMR) and the treatments received during hospitalisation. Continuous variables were expressed as mean and standard deviation; discrete variables, as percentages. Associations between related quantitative variables were analysed using the Student's *T*-test for related means.

Forty-eight patients were assessed for ARF, with an average of 17 visits per patient. The referrals came from Cardiology and Heart Surgery (33%), Internal Medicine (13%), Pulmonology (19%), Digestive Medicine and Neurology (19%); the rest were miscellaneous. Ten of these patients (21%) had previously been admitted to the Intensive Care Unit (ICU). Average age was 71 ± 10.5 years. 69% were male and the average hospital stay was long: 30.5 ± 21.7 days.

In 25% of cases, ARF was related to symptoms of heart failure; a septic procedure in 27%; volume depletion or a drug in 31%; and 17% were classified multi-factorial. The main comorbidities were: 52% diabetes, 56% heart disease, 43% peripheral vascular disease and up to 50% had a prior history of CKD.

Moreover, 71% presented with hypoalbuminaemia; 65% with low blood pressure in the preceding days, 54% presented with hypovolaemia; 6% with rhabdomyolysis; and 10% with third-spacing.

With regard to other factors¹⁻³: 21% had received NSAIDs in previous days; 60%, ACE inhibitors/angiotensin II receptor antagonists (ARBs); 25%, other drugs (aminoglycosides or chemotherapy); 21%, metformin; 16%, iodinated contrast; and, in 40% of cases, serum creatinine monitoring was not always performed daily.

Evolution: 12% required admission to ICU, 25% required haemodialysis during hospitalisation and 10% began a definitive haemodialysis programme. Kidney function remained impaired (creatinine at discharge 1.91 ± 0.75 vs. 1.27 ± 0.50 mg/dl), at 6 months (1.54 ± 0.86 vs. 1.33 ± 0.63 mg/dl), 12 months (1.68 ± 0.84 vs. 1.33 ± 0.56 mg/dl) and 24 months (1.67 ± 0.70 vs. 1.29 ± 0.52 mg/dl), with *p* = 0.001 in all comparisons.

A 66% of patients were followed in our Nephrology Clinic. Four patients died while in hospital and 15 after discharge (total mortality at 2 years: 39.5%), mainly due to cardiovascular and infectious causes, although five patients had advanced oncological diseases.

There are a large number of known risk factors for the development of ARF¹⁻⁴: age, CKD, diabetes, sepsis and

DOI of original article:

<http://dx.doi.org/10.1016/j.nefro.2017.03.008>.

[☆] Please cite this article as: Rufino Hernández JM, Rodríguez NZ, Adanero CR, Sellares VL, Torres A. Fracaso renal agudo en un hospital de tercer nivel, causa relevante de enfermedad renal crónica y mortalidad a medio plazo. *Nefrología*. 2017;37:657–658.